The efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) and vinblastine combined with interferon in nude mice xenografts of human renal cell carcinoma

International Journal of Oncology

Volumn 12, Issue 6, 1998, Pages 1367-1372

  Rohde, Detlef ^a   Goertz, Markus ^a   Blatter, Johannes ^b   Jakse, Gerhard ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

2 ,2 difluorodeoxycytidine; Interferon; Renal cell carcinoma; Xenograft

Indexed keywords

ALPHA INTERFERON; CYTOKINE; CYTOSTATIC AGENT; GEMCITABINE; HUMAN SERUM ALBUMIN; INTERFERON; VINBLASTINE;

ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL DIVISION; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0031865289     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.6.1367     Document Type: Article

References (24)

1. DeKernion JB: Treatment of advanced renal cell carcinomatraditional methods and innovative approaches. J Urol 130: 2-7, 1983.
2. Sertoli MR, Brunetti I, Ardizzoni A, Falcone A, Guarneri D, Boccardo F, Martorana G, Curotto A, Siccignano A, Rosso R and Santi L: Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. Am J Clin Oncol 12: 43-45, 1989.
3. Bergerat JP, Herbrecht R, Dufour P, Jacqumin D, Bollack C, Prevot G, Bailly G, de Garris S, Juraschek F and Oberling F: Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer. Cancer 62: 2320-2324, 1988.
4. Atzpodien J, Kirchner H, Haenninen EL, Deckert M, Fenner M and Poliwoda H: Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 29A (Suppl 5): 6-8, 1993.
5. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB: Evaluation of the anti-tumor activity of Gemcitabine (2′,2′-Difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422, 1990.
6. Huang P and Plunkett W: Induction of apoptosis by gemcitabine. Semin Oncol 22 (Suppl 11): 19-25, 1995.
7. Rohde D, Goertz M, Hayn H, Cremer U and Jakse G: Interferon-alpha and gemcitabine (2′,2′-difluorodeoxycytidine) in adult and pediatric renal tumors. Int J Oncol 11: 623-627, 1997.
8. Mertens WC, Eisenhauer EA, Moore M, Venner P, Stewart D, Muldal A and Wong D: Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4: 331-332, 1993.
9. DeMulder PHM, Weissbach L, Jakse G, Osieka R, Blatter J and Ermisch S: Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37: 491-495, 1996.
10. Rohde D, Hayn HK, Blatter J and Jakse G: The efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines. Int J Oncol 12: 1361-1366, 1998.
11. Naito S, von Eschenbach ACC, Giavazzi R and Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46: 4109-4115, 1986.
12. Otto U, Huland H, Baisch H and Kloeppel G: Transplantation of human renal cell carcinoma into NMRI nu/nu mice. II. Evaluation of response to vinblastine sulfate monotherapy. J Urol 131: 134-138, 1984.
13. Baisch H, Otto U and Kloeppel G: Antiproliferative and cytotoxic effects of single and combined treatment with tumor necrosis factor alpha and/or alpha interferon on human renal cell carcinoma xenotransplanted into nu/nu mice: cell kinetic studies. Cancer Res 50: 6389-6395, 1990.
14. Fossa SD, Marinelli G, Otto U, Schneider G, Wander H, Oberling F, Bauer HW, Achtnicht U and Holdener EE: Recombinant Interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results or a European multicenter phase III study. Ann Oncol 3: 301-305, 1992.
15. Kriegmaier M, Oberneder R and Hofstetter A: Interferon-alpha and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45: 758-762, 1995.
16. Poplin EA, Carbett T, Flaherty L, Tarassoff P, Redman BG, Valdivieso M and Baker L: Difluorodeoxycytidine (dFdC) - gemcitabine: a phase I study. Invest New Drugs 10: 165-170, 1992.
17. Boven E, Schipper H, Erkelens CA, Hatty SA and Pinedo HM: The influence of the schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancer. Br J Cancer 68: 52-56, 1993.
18. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, Veerma G and Peters GJ: Schedule-dependent anti-tumor effect of gemcitabine in in vivo model systems. Semin Oncol 22 (Suppl 11): 42-46, 1995.
19. Rockwell S and Grindey GB: Effect of 2′,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res 4: 151-155, 1992.
20. Wadler S and Schwartz EL: Anti-neoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473-3486, 1990.
21. Tomita Y, Watanabe H, Kobayashi H, Nishiyama T, Tsuji S, Fujiwara M and Sato S: Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells. Cancer Immunol Immunother 35: 381-387, 1992.
22. Hasui M, Saikawa Y, Miura M, Takano N, Ueno Y, Yachie A, Miyawaki T and Taniguche N: Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice. Cell Immunol 120: 230-239, 1989.
23. Kanamaru H and Yoshida O: Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay. Urol Res 17: 259-264, 1989.
24. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.